Background
Tatiana M. Prowell, MD is Associate Professor of Oncology in the Division of Women's Malignancies at the Johns Hopkins Kimmel Comprehensive Cancer Center and Breast Cancer Scientific Liaison to the U.S. Food and Drug Administration.
She was the principal architect of FDA’s policy on accelerated approval using pathological complete response as a novel regulatory endpoint in the neoadjuvant high-risk breast cancer setting, and a member of the Biden Cancer Moonshot Blue Ribbon Panel Cancer Immunology Working Group. A frequent public speaker, she is a three-time recipient of FDA’s Excellence in Communication Award. She is a past Giants of Cancer Care Award finalist, the recipient of the 2019 John and Samuel Bard Medal in Science or Medicine, and the recipient of a 2020 Webby Special Achievement Award for her effective use of social media during the pandemic.
A passionate medical educator and mentor, she was Chair of the 2020 ASCO Annual Meeting Education Committee and has served for many years on the faculty of the Vail ASCO/AACR Methods in Clinical Cancer Research Workshop, the Society for Translational Oncology Fellows’ Forum, the Dana Farber Clinical Investigator Seminar Series, and the FDA-ASCO Fellows’ Day Workshop, among several others.
Dr. Prowell staffs the second opinion breast cancer clinic and teaches in the Johns Hopkins School of Medicine MD/PhD medical ethics course and the medical oncology fellowship training program. Her areas of particular clinical and research interest include development of novel agents for breast cancer, neoadjuvant therapy for breast cancer, brain metastases, decentralized clinical trials, and the unique challenges of breast cancer in younger women.
Dr. Prowell received her BA degree from Bard College in literature and her MD degree from the Johns Hopkins School of Medicine with election to the Phi Beta Kappa and Alpha Omega Alpha honor societies. She completed her residency and fellowship training at Johns Hopkins Hospital.
She tweets as @tmprowell about cancer, public health, COVID-19, medical education, health equity, and women in medicine.